Journey Medical Corporation
DERMHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 9, 2026
Scan Results
Daily timeframeJourney Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. With a market capitalization of $224.9M, it sits in micro-cap territory. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Market Cap
$224.9M
Beta
1.10
P/E (TTM)
—
P/E (Fwd)
-132.83
EPS (TTM)
$-0.22
EPS (Fwd)
$-0.06
ROE
-23.8%
ROA
-2.1%
Cash
$25.6M
Total Debt
$25.5M
Free CF
-$5.5M
52W Change
8.7%
Annual Financials
Cash vs Debt
Where DERM stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, DERM finished 17.37% above its 150-day moving average ($6.62) and 11.96% above its 200-day moving average ($6.94). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DERM overbought or oversold?
At the September 3, 2026 close, DERM's RSI(14) was 71.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Journey Medical Corporation holds $25.6M in cash against $25.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$5.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -23.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $73.7M to $61.9M.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing DERM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.